Table 1.
Adjunctive catheter-directed thrombolysis (n=90) | Standard treatment only (n=99) | |
---|---|---|
Baseline | ||
Age (years) | 53.3 (15.7) | 50.0 (15.8) |
Women | 32 (35.6) | 38 (38.4) |
Duration of symptoms of acute DVT (days) | 6.4 (4.4) | 6.8 (4.8) |
EQ-5D index | 0.46 (0.39) | 0.63 (0.99) |
VEINES-QOL score | 50.2 (9.3) | 50.1 (10.7) |
VEINES-Sym score | 50.4 (9.3) | 49.5 (10.7) |
No risk factor for venous thrombosis | 31 (34.4) | 26 (26.3) |
Transient risk factors for venous thrombosis | ||
Surgery previous 3 months | 15 (16.7) | 13 (13.1) |
Trauma previous 3 months | 10 (11.1) | 15 (15.2) |
Short-term immobility | 20 (22.2) | 19 (19.2) |
Infection previous 6 weeks | 6 (6.7) | 9 (9.1) |
Pregnancy previous 3 months | 5 (5.6) | 3 (3.0) |
Hormonal replacement therapy | 4 (4.4) | 6 (6.1) |
Oral contraceptive pill | 3 (3.3) | 11 (11.1) |
Permanent risk factors for venous thrombosis | ||
Previous venous thrombosis | 9 (10.0) | 9 (9.1) |
Cancer | 3 (3.3) | 1 (1.0) |
Obesity | 9 (10.0) | 11 (11.1) |
Inflammatory bowel disease | 0 (0.0) | 3 (3.0) |
First degree relative with venous thrombosis | 9 (10.0) | 13 (13.1) |
Two risk factors for venous thrombosis | 26 (28.9) | 18 (18.2) |
Three risk factors for venous thrombosis | 10 (11.1) | 14 (14.1) |
Thrombophilia | ||
Heterozygous F5 6025 polymorphism | 23 (25.6) | 22 (22.2) |
Homozygous F5 6025 polymorphism | 1 (1.1) | 4 (4.0) |
Other thrombophilic factor(s) | 15 (16.7) | 13 (13.1) |
Data are mean (SD) or n (%).
DVT, deep vein thrombosis; QOL, quality of life.